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Background: The purpose of this study was to identify clinical and dosimetric factors associated with radiotherapy
induced bone injury (RIBI) following stereotactic lung radiotherapy.
Methods: Inoperable patients with early stage non-small cell lung cancer, treated with SBRT, who received 54 or
60 Gy in 3 fractions, and had a minimum of 6 months follow up were reviewed. Archived treatment plans were
retrieved, ribs delineated individually and treatment plans re-computed using heterogeneity correction. Clinical and
dosimetric factors were evaluated for their association with rib fracture using logistic regression analysis; a
dose-event curve and nomogram were created.
Results: 46 consecutive patients treated between Oct 2004 and Dec 2008 with median follow-up 25 months (m)
(range 6 – 51 m) were eligible. 41 fractured ribs were detected in 17 patients; median time to fracture was 21 m
(range 7 – 40 m). The mean maximum point dose in non-fractured ribs (n = 1054) was 10.5 Gy ± 10.2 Gy, this was
higher in fractured ribs (n = 41) 48.5 Gy ± 24.3 Gy (p < 0.0001). On univariate analysis, age, dose to 0.5 cc of the ribs
(D0.5), and the volume of the rib receiving at least 25 Gy (V25), were significantly associated with RIBI. As D0.5 and
V25 were cross-correlated (Spearman correlation coefficient: 0.57, p < 0.001), we selected D0.5 as a representative
dose parameter. On multivariate analysis, age (odds ratio: 1.121, 95% CI: 1.04 – 1.21, p = 0.003), female gender (odds
ratio: 4.43, 95% CI: 1.68 – 11.68, p = 0.003), and rib D0.5 (odds ratio: 1.0009, 95% CI: 1.0007 – 1.001, p < 0.0001) were
significantly associated with rib fracture.
Using D0.5, a dose-event curve was constructed estimating risk of fracture from dose at the median follow up of
25 months after treatment. In our cohort, a 50% risk of rib fracture was associated with a D0.5 of 60 Gy.
Conclusions: Dosimetric and clinical factors contribute to risk of RIBI and both should be included when modeling
risk of toxicity. A nomogram is presented using D0.5, age, and female gender to estimate risk of RIBI following SBRT.
This requires validation.
Keywords: Stereotactic body radiotherapy, Radiotherapy toxicity, Rib fracture, Nomogram, Non-small cell lung
cancer, Chest wall painBackground
SBRT has superior local tumor control when compared
to conventionally fractionated radiotherapy [1]. However
due to the large doses per fraction, the risk of late nor-
mal tissue toxicities such as radiation induced bone in-
jury (RIBI) such as rib fracture may be increased [2]. Rib* Correspondence: mojgan.taremi@rmp.uhn.on.ca
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reproduction in any medium, provided the orfracture following SBRT has been reported by a number
of groups [3-5] including our own [5] - we previously
found that out of 42 patients treated with 54 or 60 Gy in
3 fractions, 9 patients developed a total of 15 fractured
ribs after a median follow-up of 17 months. The median
radiation dose to the fractured rib was 50.1 Gy. The
current report explores in detail the relationship of rib
dose to subsequent rib fractures risk in a larger group
with longer follow up. The primary objective of this
study was to identify dosimetric and clinical risk factors
for RIBI. The secondary objective was to generate aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factors.
Methods
From Oct 2004 to Dec 2008, 127 medically inoperable
patients with T1-2N0M0 non-small cell lung carcinoma
(NSCLC) were treated on a prospective institutional re-
search ethics board-approved lung SBRT protocol at
Princess Margaret Hospital. Written consent was
obtained to participate on study and to collect the data
for publication. Patients were treated with several dose
fractionation schedules: 5 Gy × 10 fractions (n = 12), or
7.5 Gy × 8 fr (n = 10) for centrally located tumors, and
for peripheral tumors 12 Gy × 4 fr (n = 52), 18 Gy or
20 Gy (the latter was used prior to heterogeneity correc-
tion) × 3 fr (n = 53) [6] . Ribs or chest wall were not ex-
plicitly considered a critical structure at the time of
these patients’ treatment planning. Post-treatment, the
follow up schedule included clinic visits and thoracic im-
aging - chest x-ray 6 weeks after SBRT and chest CT
scan at 3, 6, 9 and 12 months, every 6 months in the
second year and yearly thereafter. The Common Ter-
minology Criteria for Adverse Events (CTCAE) v3.0 was
used to score acute and late toxicity [7]. A subset of con-
secutive patients treated with 18 or 20 Gy × 3 fractions
and with more than 6 months follow up was selected for
this study as we had previously observed rib fractures in
this group and we had not observed fractured ribs with
other schedules such as 48 Gy in 4 fractions or 50 Gy in
10 fractions.
Detecting fractured ribs
Because the radiology reports inconsistently reported
fractured ribs and some rib fractures are known to be
asymptomatic [5], identification of RIBI was systematic-
ally performed in three steps: 1) abstracting information
from serial imaging reports, 2) review of all serial follow
up imaging by two independent observers (a radiation
oncology fellow and a radiology fellow). Any cases with
discrepancy were discussed to obtain agreement, 3) 20%
of all RIBI events were reviewed randomly by a staff
radiologist resulting in 100% agreement on the fracture
site and 88% agreement on the fracture date (defined as
the date that the first sign of periosteal distortion was
observed). In the cases with date discrepancy, the radi-
ologist detected the fractured ribs on the scan performedTable 1 Common Toxicity Criteria for Adverse Events v3.0 (CT
Adverse event Grade 1 Grade2
Fracture Asymptomatic, Radiologic
findings only
Symptomatic but non-displ
Pain Mild pain not interfering
with function
Moderate pain, Pain or ana
interfering with function bu
interfering with ADL6 months earlier. Grading of rib fractures was performed
using the radiological as well as clinical prospectively
collected toxicity data, as per CTCAE v3.0 [7], rib frac-
tures were graded radiologically and clinically from pro-
spective toxicity data (Table 1).Dosimetric evaluation
The majority of the patients had a respiratory-correlated
CT scan (4D CT) for their treatment planning (32/46
patients, 70%). In the remaining 14 patients (treated
early in our SBRT program), 4D CT was used to assess
tumor motion, but not for treatment planning. Typically
the primary data set used for treatment planning was
the maximum exhale phase of the 4D CT, and less often
a helical CT data set.
To obtain dosimetric rib data, each rib was individually
contoured on the primary CT data set used for SBRT
treatment planning. Ribs were delineated from the costo-
vertebral to the costosternal/costocartilage area bilaterally,
using threshold contouring tools (1080 to 2400 HU) and
with manual review and correction in the radiation treat-
ment planning system (Pinnacle, v8.0, Philips Medical Sys-
tems, Fitchburg, WI, USA). A representative diagnostic
CT scan showing the fractured rib(s) for each patient with
RIBI was registered to the treatment planning CT scan
using the fractured rib as the region of interest for image
fusion. The fracture site was contoured by a single obser-
ver (MT) and 3D CT registration information (x, y and z)
for each fractured rib and callus were documented for
quality assurance (QA) purposes. A staff radiation oncolo-
gist reviewed and approved a subset of the contoured frac-
tures with high levels of agreement. It is important to note
that although the analysis was performed using the max-
imum point dose to the ribs, in 35 fractures (14 patients)
this was not the same as the maximum dose to the frac-
ture site. The most likely explanation was considered to
be contouring subjectivity and difficulty in determining
the exact fracture site boundaries.
The dose calculation grid (resolution of 0.25 cm ×
0.25 cm × 0.25 cm) was adjusted in all patients to cover
all ribs and each SBRT plan was re-computed with het-
erogeneity correction [8] while maintaining the planned
monitor units.
Resulting planning data was exported using the RTOG
format and the dosimetric information extracted usingCAE) for fracture and pain
Grade3 Grade4 Grade5
aced Symptomatic and displaced or open
wound with bone exposure
Disabling
lgesics
t not
Sever pain, pain or analgesics Disabling -
severely interfering with ADL
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Research) [9].Data collection and analysis
Clinical patient data was extracted from the prospectively
collected institutional SBRT database. This included: age,
sex, comorbidities (chronic obstructive pulmonary disease
(COPD), diabetes mellitus (DM)), number/location/date
of fractured ribs, history of traumatic rib fractures, tumor
size, date of SBRT treatment, date of last follow up or
death and a history of cancer metastasis to the bone.
Dosimetric data extracted from the re-computed plans
and dose volume histogram (DVH) included: rib DV
(minimum absolute dose received by volume V), ribs VD
(absolute volume receiving at least dose D), maximum/
mean/median point dose to the ribs, GTV (gross tumor
volume), the minimum 3D distance between the GTV
and any rib, the minimum 3D distance between the
GTV and any fractured ribs, and cumulative dose-
volume histogram (DVH) for each individual rib.
The correlation between dose and volume was exam-
ined using the Spearman correlation. Univariate logistic
regression was used to test the association of various
predictors with the risk of fracture. Since each patient
could have multiple fractures, repeated measures have
been taken into consideration.
A modified stepwise model fitting process was used to
select the best fit multivariate model. Maximum likeli-
hood estimation was used to select thresholds for dose
and volume. All analyses were performed using SAS v9.1
for Windows TM and all reported p-values were 2-sided,
a p-value of < 0.05 was considered significant. Using the
multivariate model, a nomogram was generated and itsTable 2 Clinical factors in 46 patients treated with lung SBRT
Patients
Median Age (year)
(range)
Median follow up time (Months)
(range)
Number of patients with rib fracture
Number of fractured sites
8 pts with DM* Patients with no fracture
Patients with fracture
29 pts COPD** Patients with no fracture
Patients with fracture
Mean (± SD) Tumor size (cm)
Closest 3 dimensional distance from tumor to the ribs (cm)
(range)
*DM: Diabetes Mellitus, ** COPD: Chronic Obstructive Pulmonary Disease.receiver operating characteristic (ROC) calculated to as-
sess its discrimination power.
A final logistic model was generated estimating RIBI
risk at a median follow up of 25 month based on the ‘all
rib’ analysis.
Probability of fracture:
P ¼ 1
1þ e aþhXð Þ
P is the probability of a fracture (1), e is the base of
the natural logarithm (about 2.7); a and b are the para-
meters of the model. The value of a yields P when X is
zero, and b adjusts how quickly the probability changes
with changing X.
Results
Patient characteristics
From Oct 2004 to Dec 2008, 48 consecutive patients
were treated with 18 or 20 Gy × 3 fractions and followed
for > 6 months, two were excluded from this analysis -
one had rib fracture at baseline, pre-SBRT, the other had
rib fracture associated with a bone metastasis. Thus, 46
patients with 49 tumors (3 patients had 2 tumors) were
analyzed. Median age was 73 years (range: 48 to 89 years)
and median follow up was 25 months (range: 6 to 51 m).
There were 22 male and 24 female patients with similar
median age (73 year) but median follow-up was slightly
higher in female group (26.2 vs. 22.7 months) as shown
in Table 2. 17 of 46 patients (37%) were identified as
having developed rib fractures with a total of 41 frac-
tured ribs and 43 fracture sites. Of 17 patients with frac-
tured ribs, 11 (with 30 fractures) were female and 6
(with 13 fractures) were male (Table 2).Total Female Male
46 24 22
72.8 72.6 72.8
(48.3-89.6) (58-89.6) (48.3-85.5)
24.9 26.2 22.7
(6-51.2) (6-51.2) (7.6-48.5)
17 11 6
43 30 13
6 1 5
2 0 2
18 9 9
11 7 4
2.6 ± 1.2 2.7 ± 1.2 2.6 ± 1.2
0.96 1.01 0.88
(0 – 3.28) (0 – 3.28) (0 – 2.76)
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Figure 1. In patients with multiple rib fractures, the frac-
ture sites were in proximity to each other (Table 3). Two
patients had bilateral fractured ribs however the dose to
the fractured ribs was so low in one of these patients (pt
# 9 in table 3) that radiotherapy cannot be considered
the primary risk factor. In such cases other clinical fac-
tors may play the more important role.
Median time to development of a fractured rib was
21 months (range: 7 - 40 m) as shown in Figure 2. Thir-
teen of 17 patients with rib fracture had at least two
fractured sites. Detailed dosimetric information for each
fractured rib and the callus in 17 patients with rib frac-
ture has been summarized in table 3. Of patients identi-
fied with fractures, the original radiologic reports did
not report fracture in 3 out of 17 patients (18%). In
those patients in whom rib fractures were reported, the
number and first reported date of fracture were incom-
plete. Overall, a total of 15 out of 41 rib fractures (37%)
were not noted in the original report and the first date
of reported fracture was on average 5 months (range: 0
to 18 m) later than was detected in this study.
Clinical (chest wall pain) and radiologic (rib fracture)
toxicities are shown in Figure 3. Chest wall pain was
detected in 7/29 patients (24%) without rib fracture and
in 14/17 patients (82%) with rib fractures. Although in
the majority of patients fractured ribs remain unhealed,
patients did not require narcotic pain medications for a
long time. In all patients except one (with 6 fractured
ribs), pain became more stable after 6–8 months.
Patients with chest wall pain received higher dose of
radiation to the ribs compared to patients without chest
wall pain (62.76 Gy, range: 28.4-88.05 Gy vs. 47.21 Gy,
range: 15.9-73.19 Gy; p value: 0.008) (Table 4).Posterior Chest wall
Figure 1 Anatomic locations of 41 fractured ribs in 17 patients with RDosimetric factors
After re-contouring, 1095 ribs were available for analysis;
in some patients some of the whole ribs could not be
contoured because they were not fully included in the
planning CT scan images (less than 5% in ribs 1 and 2
but more than 50% in ribs 11 and 12).
All individual fracture sites were contoured separately
however in the majority of cases (35 fracture sites in 14
patients) the maximum dose to the fracture site was not
the maximum dose to the fractured rib therefore as
mentioned above the analysis was performed using the
maximum point dose to the ribs.
Analysing per patient, using the maximum dose
received by any rib in each patient, a significant differ-
ence (p = 0.02) was noted between 29 patients with no
rib fracture (50.2 Gy ± 17.7 Gy, range: 21.6 to 73.2 Gy)
vs. 17 patients with rib fracture (63.7 Gy ± 15.3 Gy,
range: 26.6 to 88 Gy). There was no significant differ-
ence (p = 0.09) between the mean maximum dose to the
first fractured rib (52 Gy +/−24.9 Gy, range: 3.9 -
76.4 Gy) compared to subsequent fractured ribs (50 Gy
+/− 19 Gy, range: 19.6 - 71.2 Gy).
Assuming each rib was independent, out of 1095 ribs,
41 had fractures and 1054 did not. In non-fractured ribs,
the mean maximum point dose was 10.5 Gy ± 10.2 Gy
(range: 0.2 to 87 Gy) compared to 48.5 Gy ± 24.3 Gy
(range 0.6 to 88 Gy) in fractured ribs; this was statistical
significantly different (p < 0.001).
While many dosimetric parameters were correlated
with rib fracture, D0.5 and V25 appeared to have the
highest individual correlations (Figure 4).
To evaluate the impact of including ribs receiving very
low dose of radiotherapy on correlations, ribs receiving
less than 1, 5, 10, 15, 20 and 25 Gy were sequentiallyAnterior chest wall 
IBI.
Table 3 Max point dose to the callus in 17 patients with rib fractures (43 calluses in 41 fractured ribs)
Patients
N = 17
Number of rib
fractures N = 41
Callus
N = 43
Callus max point
dose (Gy)
Highest max Point
dose to fractured
rib (Gy)
Highest max point
dose to callus (Gy)
Lowest max point
dose to fractured
rib (Gy)
*Mean
dose (Gy)
1 2 68.52 Lt rib 5 68.52 Lt rib 5 61.85 Lt rib 6 65.18
Lt rib 5 68.52
Lt rib 6 62.40
2 6 76.39 Rt rib 5 73.6 Rt rib 5 6.80 Rt rib 11 41.59
Rt rib 4 36.27
Rt rib 5 73.6
Rt rib 6 29.45
Rt rib 9 6.06
Rt rib 10 7.58
Rt rib 11 1.16
3 2 64.63 Rt rib 4 61.54 Rt rib 4 23.15 Rt rib 3 43.89
Rt rib 3 23.15
Rt rib 4 61.454
4 4 88.05 Rt rib 6 87.91 Rt rib 6 13.17 Rt rib 4 50.61
Rt rib 3 24.07
Rt rib 4 13.17
Rt rib 5 68.39
Rt rib 6 87.91
5 1 Rt rib 4 48.54 50.10 48.54 48.54 49.32
6 2 59.56 Rt rib 5 29.76 Rt rib 5 25.03 Rt rib 4 42.29
Rt rib 4 25.03
Rt rib 5 29.76
7 2 69.36 Rt rib 4 58.79 Rt rib 3 49.05 Rt rib 4 59.20
Rt rib 3 58.79
Rt rib 4 49.5
8 1 Rt rib 5 35.12 35.84 35.12 35.12 35.48
9 3 21.82 Rt rib 7 0.7 Rt rib 7 0.45 Rt rib 8 11.26
Lt rib 7 0.48
Rt rib 7 0.7
Rt rib 8 0.45
10 2 71.39 Rt rib 3 70.84 Rt rib 3 23.37 Rt rib 2 47.38
Rt rib 2 23.37
Rt rib 3 70.84
11 4 75.34 Lt rib 6 72.59 Lt rib 6 6.13 Lt rib 8 40.73
Lt rib 5 68.39
Lt rib 6 72.59
Lt rib 7 48.85
Lt rib 8 3.25
12 3 69.86 Rt rib 4 69.86 Rt rib 4 10.64 Rt rib 5 40.25
Rt rib 4 69.86
Rt rib 5 10.64
Rt rib 5 68.37
Rt rib 6 32.04
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Table 3 Max point dose to the callus in 17 patients with rib fractures (43 calluses in 41 fractured ribs) (Continued)
13 2 68.49 Lt rib 7 66.40 Lt rib 7 12.16 Lt rib 6 40.32
Lt rib 6 62.03
Lt rib6 12.16
Lt rib 7 66.40
14 2 50.38 Lt rib 9 50.38 Lt rib 9 44.04 Lt rib 8 47.21
Lt rib 8 44.04
Lt rib 9 50.38
15 3 72.44 Lt rib 7 69.07 Lt rib 7 23.46 Rt rib 5 47.95
Rt rib 5 23.46
Lt rib 7 69.07
Lt rib 8 66.96
16 1 Rt rib 11 0.10 0.56 0.1 0.10 0.33
17 1 Rt rib 5 44.07 64.18 44.07 44.07 54.12
Max point dose to the fractured rib was not located on the callus in 14/17 patients.
* Mean dose is the average of the lowest and highest maximum point doses to the fractured rib(s).
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Both D0.5 and V25 were well correlated in all sub-groups.
As D0.5 and V25 were cross-correlated (Spearman correl-
ation coefficient: 0.57, p < 0.001), we selected D0.5 as a
representative dose parameter that could be included in
subsequent modeling efforts. Using D0.5, a dose-event
curve was constructed estimating risk of fracture from
dose at the median follow up of 25 months after treat-
ment (Figure 5).
Combining clinical and dosimetric factors
On univariate analysis, correlations with RIBI were
found with age (p = 0.045), but not with gender, COPD
or diabetes. In terms of dosimetric factors, all Dx and Vx
were significant on univariate analysis, as discussed
above; D0.5 was used for multivariate analysis.Pr
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Figure 2 Kaplan Meier curve for fractured rib as an event
(n = 46 patients). Dashed lines indicate 95% confidence intervals.On multivariate analysis, age (p = 0.003), female gen-
der (p = 0.003) and rib D0.5 (p < 0.0001) were variables
that were significantly associated with RIBI (Table 5).
A nomogram was generated based on this multivariate
model. The nomogram estimates risk of RIBI at 25 months
median follow up in our cohort of patients (Figure 4)
based on pre-treatment factors including age, gender and
D0.5 in patients treated with 54 or 60 Gy in 3 fractions.
Although, the nomogram still needs validation, it may
be helpful in estimating the risk of rib fracture in an indi-
vidual patient. For example estimated risk of rib fracture
in a 75 year old (55 points for age) lady (25 points for fe-
male gender) with D0.5 of 60 Gy (85 points for dose) is
about 65% (total of 165 points as shown in Figure 6),
which is much higher than in a same age man with the
same planning criteria (risk of rib fracture of 15-20%). This
emphasizes the importance of clinical factors when esti-
mating the risk of RIBI.
A receiver operating characteristic (ROC) curve for
the nomogram demonstrated an area under the curve
(AUC) of 0.93.0
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Figure 3 Grading of chest wall pain (n = 21 patients with
reports of chest wall pain > 0) and rib fractures (n = 17 patients,
43 fractures) based on CTCAE criteria.
Table 4 Mean maximum point dose to the ribs in patients
with or without chest wall pain
Group Number of
patients
Mean maximum
point dose (Gy)
p-value
(range)
Patients with
chest wall pain
21 62.76 0.008*
(28.4 - 88.05)
Patients without
chest wall pain
25 47.21
(15.9 - 73.19)
*Wilcoxon-Mann-Whitney test was used to obtained the p-value.
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Radiation induced bone injury (RIBI) has been reported
as the radiotherapy toxicity in a number of studies
[2,3,5,6,10-14]. The incidence of RIBI in patients treated
with lung SBRT has been variably reported as ranging
from 0% to more than 50% [4,5,15]. The variability may
be due to differences in treatment technique and dose-
fractionation, reported outcomes, selection criteria, fol-
low up procedures, whether or not available radiography
was reviewed again for rib fractures, and the process of
analysis. For example, Pettersson et al. [3] analyzed the
planning information of 33 patients treated with 45 Gy
in 3 fractions. With a median follow up of 29 months,
13 fractured ribs were identified in 7 patients. They esti-
mated that delivering 27.3 Gy to 2 cm3 (D2) of ribs was
associated with a 50% risk of fracture. In this study ribs
receiving less than 21 Gy were excluded. In our study
the value of D0.5 had the maximum likelihood (MLL)
value; however we included all the ribs in our analysis.
To evaluate the impact of including the ribs receiving
low dose RT, we repeated the MLL curves excluding the
ribs receiving < 25 Gy in a stepwise process however, the
value of D0.5 remained the significant MLL cut point. In
our cohort, a 50% risk of rib fracture was associated with
a D0.5 of 60 Gy.
This was consistent with data from Stephans et al. [12]
who found that in 45 patients treated with 60 Gy in 3
fractions there was no chest wall toxicity observed with-140
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Figure 4 Maximum likelihood curve for fractured ribs. Dx: Absolute do
receiving certain dose (15-50 Gy) of the ribs.a minimum absolute chest wall point dose of less than
67.5 Gy.
Similar findings have been reported by Onishi et al. in
abstract form [16]. In this study with a median follow up
of 33 months, RIBI was observed in 41 (23.2%) patients.
BED calculation with α/β ratio of 3 was used for dose
comparison. There was no rib fracture observed in
patients in whom the maximum point dose to the chest
wall was less than 218 BED (approximately equal to
40 Gy in 3 fractions) but rib fracture was considered “in-
evitable” when the BED was more than 250. Although
there is controversy surrounding the use of the LQ
model in SBRT [17,18] this data supports a dose–
response relationship for rib fracture. Explanations for
Pettersson et al. [3] having a 50% risk of RIBI with lower
SBRT doses could include confounding clinical variables,
and the small sample size. The relationship between
delivered dose to the ribs and the risk of fracture has
also been studied by Chollet et al. [19] who found no rib
fractures in 15 patients treated with 50 Gy in 5 fractions
within the median FU of 13 months. Although a lower
maximum point dose to the chest wall might be related
to the lack of event in these patients, the potential risk
for chest wall toxicity should be weighed carefully
against the potential benefit of higher SBRT dose in
terms of tumor control probability [20].
In our study, D0.5 and other dosimetric parameters were
all correlated with the risk of developing RIBI but inclu-
sion of clinical variables, notably age and gender, improved
the predictive model. We have created a nomogram based
on these 3 dosimetric and clinical parameters. As an illus-
tration (Figure 6), a 75 year old woman who received a
planned dose of 60 Gy to 0.5 cc of a rib has an estimated
65% risk of RIBI within the first two years of follow up. A
man of the same age and with the same D0.5 would in
contrast have about a 15% risk of RIBI.
Strengths of our study include the long median follow
up time (25 months) and careful radiologic review. As
RIBI is a late toxicity, to accurately assess event rate, it is
important to follow these patients closely, not only with
clinical exam but because many rib fractures are-140
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0
15 20 25 30 35 40 45 50
Lo
g-
Li
ke
lih
oo
d
Vx
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Figure 5 a: D0.5 for patients with fractured ribs (pink triangle) and without fractured ribs (Green diamond); calculated probability of
fracture (blue diamond) at the median follow up of 25 months based on D0.5. b: Distribution of 17 patients with fractured rib per D0.5
dose groups (10 Gy bin size), and calculated probability of fracture (blue diamond).
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ology reports did not always identify the presence of a
new rib fracture. Fifteen fractured ribs were not reported
and overall there was an average of 5 months latency in
reporting fractured ribs. This highlights the importance
of spreading knowledge in the radiology community
about the pattern of late toxicity that can be seen with
SBRT. Furthermore, to minimize potential sources of
error, our group of patients was selected to be as
homogenous as possible - all had more than 6 months fol-
low up and all were treated with 54 or 60 Gy in 3 frac-
tions. Additional strengths are: prospective data collectionas part of REB-approved institutional protocol [6], exclu-
sion of patients with other causes of rib fractures such as
bone metastases or trauma, standard contouring of ribs
and planning, evaluating multiple different DVH values,
and including clinical and dosimetric factors.
Symptomatic chest wall toxicity has been observed
in patients with lung cancer treated with stereotactic
radiotherapy [21,22]. Dunlap et al. [4], reported chest wall
pain in 20 and rib fracture in 5 out of 60 lung SBRT
patients treated with various dose fractionation schedules.
Their analysis only included those patients with tumors
located within 2.5 cm of chest wall or those whose
Table 5 Univariate and multivariate analysis on
predictors for rib fractures (repeated measures have
been taken into consideration)
Univariate analysis
Predictor Odds Ratio 95% CI p-value
Age (years) 1.083 1.002 - 1.172 0.045
Gender-F 2.256 0.656 - 7.756 0.2
Diabetes Mellitus-yes 0.51 0.091 - 2.876 0.45
COPD-yes 0.97 0.275 – 3.386 0.96
Tumor size 1.037 0.982 -1.095 0.19
Smallest 3D distance
between the tumor and
closest rib
0.408 0.152 – 10.970 0.07
Multivariate analysis
Age (year) 1.121 1.04 – 1.21 0.003
Gender-F 4.43 1.68 – 11.68 0.003
D0.5 1.0009 1.0007 - 1.0011 <0.0001
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With median follow up of 11 months, they reported 30%
risk of chest wall pain or rib fracture if 35 cm3 of the chest
wall received more than 30 Gy. The fact that the ribs were
not evaluated separately and the patients received several
dose fractionation schedules makes it difficult to compare
their results to the current study. In our cohort, 14
patients with rib fracture had chest wall pain (in compari-
son to 7 patients without rib fracture). The majority of
these cases had grade 1 or 2 chest wall pain however; there
were 3 cases of grade 3 chest wall pain in the group of
patients with rib fracture (Figure 3). Moreover ribs
received statistically significant higher dose in patients
with chest wall pain in comparison to ones without chest
wall pain (Table 4). This justifies an attempt to reduce thePoints
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Figure 6 RIBI nomogram based on gender, age and D0.5 in 46 patient
risk of rib fracture at median follow up of 25 month). Risk of rib fractu
Gy (within a median FU of 2 years)is about 65%.dose to the ribs if and when possible. The dose constraints
identified are most useful in situations where the tumor is
sufficiently far away from ribs that planning and
optimization efforts to reduce dose can be useful without
decreasing tumor dose or increasing lung dose. Attention
to radiation planning technique in order to limit hot
spots/D0.5 in the chest wall and adjacent ribs, without
compromising PTV coverage may be beneficial. Currently,
it is our institutional policy to contour any ribs adjacent to
the PTV and attempt to spare them without compromis-
ing PTV coverage. Advanced RT techniques such as
VMAT and IMRT might also help with this. Our group
has chosen to use the 48 Gy in 4 fraction schedule for
tumors less than 3 cm that are immediately adjacent to the
chest wall as we have not yet observed a high rate of frac-
ture in this group while tumor control remains excellent.
Our study had a number of limitations. First, the study
set was limited to patients with three fractions; it is un-
clear if the model derived will have similar correlations
with RIBI in patients treated with different dose fractio-
nations. Second, due to the small sample size and lim-
ited events, it was not possible to divide the data into
training and testing sets to allow internal model valid-
ation. Therefore, our nomogram model requires subse-
quent validation on another dataset. Nevertheless, it may
help to improve the general understanding of RIBI risk
and to emphasize the need for clear discussion with po-
tentially high-risk patient groups who are treated with
SBRT. Third, the clinical factors explored in the current
study were limited by data availability. There are other
clinical factors that could potentially play a role in RIBI,
such as cough, corticosteroid use, and presence of osteo-
porosis that should be explored in future investigations.
In addition, the dosimetric study was based on rigid ra-
ther than deformable registration and on planned rather40 50 60 70 80 90 100
5 70 75 80 85 90
0 3000 3500 4000 4500 5000 5500 6000 6500 7000
0 100 120 140 160 180 200 220
01 0.1 0.25 0.5 0.75 0.95
s treated with SBRT at Princess Margaret Hospital (Estimating
re in a 75 year old lady treated with 54 Gy in 3 fractions and D0.5 of 60
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http://www.ro-journal.com/content/7/1/159than received dose. Several factors may play a role in de-
termining the actual dose received by the ribs such as
variation in daily positioning and breathing motion. As-
sessment of cone beam set up images in combination
with deformable image registration and dose accumula-
tion may help to identify the impact of these factors and
suggest further risk reduction strategies.
Conclusions
Radiation oncologists, diagnostic radiologists and other
specialists who see patients post SBRT, as well as
patients themselves should be aware of and informed
about the late toxicities related to lung SBRT, including
rib fracture. Risk factors for RIBI include increasing age,
female gender, and high RT dose to 0.5 cc of nearby ribs.
A nomogram incorporating these factors may be useful
in estimating individual patient risk, though internal and
external validation of this model is needed.
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